GLP-2 Derivative Composition for Steroid-Refractory GVHD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for graft-versus-host disease, particularly steroid-refractory graft-versus-host disease, have low response rates and significant side effects, necessitating the development of new drugs for effective prevention and treatment.
Innovation Solution
A pharmaceutical composition containing a glucagon-like peptide-2 (GLP-2) derivative or its long-acting conjugate, which can be administered alone or in combination with steroids, to prevent or treat graft-versus-host disease, including steroid-refractory cases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose steroids are used to treat steroid-refractory graft-versus-host disease, then the disease suppression effect is improved, but the survival rate remains low and side effects increase
Solution Approach 1:
The patent changes the pharmacological parameter by introducing a JAK1/2 inhibitor (ruxolitinib) with a different mechanism of action compared to conventional steroids. This inhibitor targets the JAK-STAT signaling pathway, providing a novel therapeutic approach that improves survival rates while maintaining disease suppression efficacy in steroid-refractory GVHD patients.
Solution Approach 2:
The patent uses an intermediary substance (JAK1/2 inhibitor) that mediates between the disease pathology and the therapeutic response. By blocking the JAK1/2 kinase enzymes, the inhibitor prevents downstream signaling that drives GVHD pathology, thereby improving survival without the severe side effects associated with high-dose steroids.
2Reliability
If cyclosporine A is used at high doses to suppress T cell activation, then the disease treatment effect is improved, but renal toxicity and side effects increase
Solution Approach 1:
The patent extracts the essential therapeutic function of suppressing T cell activation andGVHD pathology, then achieves this through a different mechanism (JAK1/2 inhibition) rather than relying on cyclosporine A. This extraction allows maintaining the beneficial immunosuppressive effect while eliminating the harmful renal toxicity associated with cyclosporine A.
Solution Approach 2:
The patent substitutes the mechanical/chemical mechanism of cyclosporine A (calcineurin inhibition) with a different biochemical mechanism (JAK1/2 kinase inhibition). This substitution maintains the immunosuppressive function while avoiding the specific renal toxicity profile of cyclosporine A, representing a paradigm shift in the therapeutic approach.
3Reliability
If conventional immunosuppressant compounds are used to treat graft-versus-host disease, then the disease response is improved, but the response rate and survival rate remain low
Solution Approach 1:
Instead of continuing to use conventional immunosuppressants that have shown limited efficacy, the patent inverts the approach by using a JAK1/2 inhibitor that targets a different pathway. This inversion of the therapeutic strategy leads to improved response rates and survival, demonstrating that a fundamentally different mechanism is needed for effective treatment.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to a prophylactic or therapeutic use of a GLP-2 derivative and/or a long-acting conjugate thereof for graft-versus-host disease. The present invention also relates to a prophylactic or therapeutic use of a GLP-2 derivative and/or a long-acting conjugate thereof for steroid-refractory graft-versus-host disease to use the GLP-2 derivative and/or a long-acting conjugate thereof in combination with steroid.